ICON Development Solutions Enhances Regulatory TeamDublin, Ireland, October 1st 2007 – ICON Plc (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Dr David Shaw to the position of Senior Director, EU Regulatory Affairs at ICON Development Solutions. This newly created role will strengthen the division’s capabilities in early and late stage regulatory consulting and post-licensing services.
Thomas Frey President, of ICON Development Solutions, commented, “We are delighted that David has joined ICON. He will be a great asset to our business. David brings a wealth of experience with over 25 years of extensive drug development expertise in the fields of regulatory affairs and non-clinical safety assessment.”
Prior to joining ICON Development Solutions, Dr Shaw was founder and Director of PharmDev Consulting Services. He has also held senior leadership roles in Johnson and Johnson, where he was Director of Global Pre-clinical Development and at Elan where he held the role of Director, Development and Regulatory Affairs in the field of HIV. He has also managed international regulatory affairs programmes for some of the worlds leading pharmaceutical companies.
Dr Shaw said, “ICON Development Solutions has a reputation for delivering excellent service to its customers. I am looking forward to joining the team and to working with our customers to optimise their drug development programmes.”
About ICON Development Solutions
With expertise in clinical pharmacology, regulatory affairs, pharmacokinetics, pharmacometrics, biopharmaceutics and bioanalytical, ICON Development Solutions specialises in the strategy, management and execution of product development and early phase clinical development. ICON Development Solutions has conducted over 1000 clinical studies and has designed the product development plans for over 50 products. For more information visit www.icondevsolutions.com
About ICON
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 1,900 development projects and over 2,300 consultancy engagements across all major therapeutic areas. ICON currently has approximately 5,150 employees, operating from 63 locations in 33 countries. Further information is available at www.iconplc.com
Back to press releases
Thomas Frey President, of ICON Development Solutions, commented, “We are delighted that David has joined ICON. He will be a great asset to our business. David brings a wealth of experience with over 25 years of extensive drug development expertise in the fields of regulatory affairs and non-clinical safety assessment.”
Prior to joining ICON Development Solutions, Dr Shaw was founder and Director of PharmDev Consulting Services. He has also held senior leadership roles in Johnson and Johnson, where he was Director of Global Pre-clinical Development and at Elan where he held the role of Director, Development and Regulatory Affairs in the field of HIV. He has also managed international regulatory affairs programmes for some of the worlds leading pharmaceutical companies.
Dr Shaw said, “ICON Development Solutions has a reputation for delivering excellent service to its customers. I am looking forward to joining the team and to working with our customers to optimise their drug development programmes.”
About ICON Development Solutions
With expertise in clinical pharmacology, regulatory affairs, pharmacokinetics, pharmacometrics, biopharmaceutics and bioanalytical, ICON Development Solutions specialises in the strategy, management and execution of product development and early phase clinical development. ICON Development Solutions has conducted over 1000 clinical studies and has designed the product development plans for over 50 products. For more information visit www.icondevsolutions.com
About ICON
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 1,900 development projects and over 2,300 consultancy engagements across all major therapeutic areas. ICON currently has approximately 5,150 employees, operating from 63 locations in 33 countries. Further information is available at www.iconplc.com